Sociedad Americana de Hirudoterapia

Chronic Otitis Externa (Investigational Adjunct)

Investigational adjunct for refractory chronic otitis externa; topical antimicrobials, aural toilet, and predisposing-factor management remain evidence-based.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for chronic otitis externa. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
¿Qué evidencia existe?
Tier C (investigational). No controlled trials. Evidence-based first-line management is otologic examination to identify the cause (eczematous, fungal, bacterial, foreign body, underlying cholesteatoma), aural toilet, topical corticosteroid drops for inflammatory disease, topical antifungal for otomycosis, topical antibiotic-steroid combinations for bacterial disease, and identification and avoidance of triggers (water exposure, cotton swab use, hearing aids).
Riesgos principales
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Periauricular placement near the ear canal carries bleeding and infection risks in already inflamed tissue
  • Aeromonas may add a second pathogen to an already infected ear
  • Bites cannot be placed inside the ear canal — that is unsafe
Quién no debería considerar esto
  • Patients without ENT evaluation to confirm the diagnosis and rule out malignant otitis externa, cholesteatoma, or tumor
  • Patients with active fungal or bacterial infection (need targeted topical therapy)
  • Diabetic or immunocompromised patients with otitis externa (high risk of skull-base osteomyelitis)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
Qué preguntar a su clínico
  • Has ENT evaluated my ear canal and ruled out malignant otitis externa or other serious causes?
  • Have appropriate topical antibiotic, antifungal, or steroid drops been tried?
  • Have aural toileting and trigger avoidance been addressed?
  • What is the published evidence base for leeches in otitis externa?
  • Where exactly will leeches be placed, and how is proximity to the ear canal managed?
  • How will worsening infection be detected during the course?
Cuándo buscar atención urgente
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Severe ear pain disproportionate to physical findings (possible malignant otitis externa, especially in diabetics)
  • Facial weakness, severe headache, or fever (could indicate skull-base osteomyelitis)
  • New hearing loss, vertigo, or persistent discharge

Qué NO significa esto

  • It does not mean leech therapy is FDA-cleared for otitis externa — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace targeted antibiotic, antifungal, or steroid topical therapy.
  • It does not exclude malignant otitis externa, cholesteatoma, or ear canal tumor.
  • It does not address triggers (water, cotton swabs, hearing aids).
  • It does not have controlled-trial evidence and adds risks in an already inflamed area.

Clinical Profile

Category
ent
ICD-10
H60.60, H60.61, H60.62, H60.63
Safety tier
high

Evidence Summary

Chronic otitis externa is inflammation of the external ear canal lasting beyond 6 weeks, often with bacterial (Pseudomonas, Staphylococcus) or fungal (Aspergillus, Candida) component. Evidence-based management includes microscopic aural toilet, topical antimicrobial drops (fluoroquinolone-corticosteroid combinations for bacterial, antifungal for fungal), wick placement in canal-stenotic cases, and addressing predisposing factors (water exposure, dermatitis of the canal, cerumen pathology, hearing-aid use). Necrotizing otitis externa in diabetic or immunocompromised patients is a surgical emergency. No published controlled trials of hirudotherapy exist for chronic otitis externa. The external auditory canal is anatomically inaccessible and high-risk; the periauricular region carries facial nerve and arterial risk.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active bacterial or fungal otitis externa
  • Necrotizing (malignant) otitis externa — surgical emergency
  • Tympanic membrane perforation
  • Ear canal placement
  • Cholesteatoma or other middle-ear pathology
  • Hearing aid in situ on affected side

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Chronic Otitis Externa (Investigational Adjunct) — Hirudotherapy Evidence | ASH